A Study to Evaluate the Efficacy and Safety of ORMD-0801 (Oral Insulin) in Patients With Type 2 Diabetes Mellitus

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 373 participants.

Also called NCT03467932

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 373 participants (enrolled count) (from the registry)
Sponsor
  • Integrium Registry lists this organization as a collaborator
  • Oramed, Ltd. Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03467932
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03467932. Randomized; quadruple masking; primary purpose treatment. Start 2018-05-29 (actual); primary completion 2019-10-21 (actual). Results posted on 2022-11-08.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Efficacy and Safety of ORMD-0801 (Oral Insulin) in Patients With Type 2 Diabetes Mellitus
Condition
T2DM (Type 2 Diabetes Mellitus)
Intervention (Drug)
Cohort A: ORMD-0801
Intervention (Drug)
Placebo oral capsule
Intervention (Drug)
Cohort B: ORMD-0801
Lead sponsor
Oramed, Ltd. (class: industry)
Collaborator
Integrium (class: industry)

Record details

Record id
cardio:ct-nct03467932
Content hash
871253c28a37879c74ef4e33bc9edb760911e74857b880544f2072711b7dc2ee